+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CAR-T Therapy Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5939602
The car-t therapy market size has grown rapidly in recent years. It will grow from $2.15 billion in 2023 to $2.55 billion in 2024 at a compound annual growth rate (CAGR) of 19.1%. The historical growth can be attributed to the rise in healthcare expenditure, increased pharmaceutical research and development (R&D) spending, and advancements in drug discovery.

The car-t therapy market size is expected to see rapid growth in the next few years. It will grow to $4.74 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%. Forecasted growth is fueled by an increase in blood cancer incidence rates, higher healthcare expenditure, a robust drug pipeline, and a heightened focus on CAR-T therapy. Key trends include R&D investments for redesigned CAR-T therapy, developing off-the-shelf allogeneic CAR-T treatment, manufacturing next-gen CAR-T cells, utilizing AI for optimization, strategic collaborations, and acquisitions to expand CAR-T therapy portfolios.

The growth of the CAR-T therapy market is significantly influenced by increased financial support from diverse organizations aimed at fostering the development and utilization of CAR-T therapy. Governmental and non-governmental bodies extend financial aid to companies operating within the CAR-T therapy market, facilitating research and development initiatives as well as aiding patients seeking treatment for acute lymphoblastic leukemia (ALL). An illustration of such support can be observed in December 2021 when the University of California San Diego School of Medicine received a substantial funding grant of US$ 4.1 million from the California Institute for Regenerative Medicine (CIRM). This grant specifically aimed at advancing the development of innovative chimeric antigen receptor (CAR-T) cell therapy. The backing provided by various organizations toward CAR-T therapy acts as a driving force propelling the market's growth.

The escalating prevalence of cancer globally stands as a pivotal factor propelling the expansion of the CAR-T therapy market. The rising incidence of cancer signifies an increased number of diagnosed cases within specific populations or regions over defined periods. This surge in cancer prevalence has spurred extensive research endeavors and investments in cancer therapies, notably cellular immunotherapies such as CAR-T therapy. These therapies mark a significant stride in oncological advancements, addressing the critical needs of cancer patients. For instance, statistics from the American Cancer Society in 2021 projected staggering figures of new cancer cases and deaths (1.9 million new cases and 608,570 deaths) anticipated in the United States that year. Hence, the mounting prevalence of cancer serves as a primary driver propelling the growth trajectory of the CAR-T therapy market.


Companies within the CAR-T therapy market are actively engaged in clinical trials aimed at assessing the efficacy of CAR-T therapy in treating multiple myeloma, a form of cancer characterized by the accumulation of cancerous cells in the bone marrow, often encroaching upon healthy blood cells. CAR-T therapy represents a potential treatment for relapsed or refractory multiple myeloma (RRMM), with CAR-T cells engineered to target the specific cells responsible for the disease. An example of this advancement can be seen in December 2021, with Novartis unveiling T-Charge, its next-generation CAR-T platform designed as a foundational framework for various new investigational CAR-T cell therapies within the Novartis pipeline. This product was in the early clinical stage (Phase I), indicating ongoing efforts to explore its potential in treating multiple myeloma.

Major companies operating in the CAR-T cell therapies market are dedicated to innovating new products such as BioCentriq to augment their profitability within the industry. BioCentriq serves as a valuable resource for organizations involved in the realm of cell and gene therapies, facilitating advancements in development, manufacturing, and research efforts, ultimately aiming to enhance patient care. For instance, in October 2023, Terumo Blood and Cell Technologies, a Japanese medical technology company, introduced BioCentriq with the objective of generating accessible public data concerning CAR-T cell manufacturing using Terumo BCT’s CGT (Cell and Gene Therapy) manufacturing platforms. In collaboration with Terumo BCT, BioCentriq strives to pioneer publicly available data focusing on swift CAR-T cell manufacturing, employing the Quantum Flex and Finia platforms. This innovative trial aims to demonstrate the efficient production of high-quality CAR-T cells, leveraging the seamless integration of Terumo BCT's technology and BioCentriq's process expertise to establish streamlined, GMP-translatable workflows.

In July 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, successfully acquired Iveric Bio for $5.9 billion. This strategic move enhances Astellas' ability to address patients at high risk of vision loss due to ocular illnesses. The acquisition leverages Iveric Bio's expertise in ophthalmology alongside Astellas' global resources, aiming to create a leading organization in the field. The transaction was subject to standard closing requirements, including approval from Iveric Bio's stockholders and regulatory approvals. Iveric Bio is a U.S.-based biotech company.

Major companies operating in the car-t therapy market report are Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd., Aeon Therapeutics, CARsgen Therapeutics, Daiichi Sankyo, Otsuka Pharmaceutical, Ono Pharmaceutical, Japan Tissue Engineering, Nipro Corporation, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune(UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Crescendo Biologics, GammaDelta Therapeutics, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen, AstraZeneca, Bayer AG, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Bluebird Bio Amgen, Regen BioPharma, OncoSec Medical Incorporated, Precision BioSciences, Bellicum, Sandoz AG, GlaxoSmithKline PLC, Elekta, SudairPharma, Janssen, Aspen, Adcock Ingram.

North America was the largest region in the CAR-t therapy market in 2023. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the car-t therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The chimeric antigen receptor -T therapy market includes revenues earned by CAR-T therapy products and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary2. CAR-T Therapy Market Characteristics3. CAR-T Therapy Market Trends and Strategies
4. CAR-T Therapy Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global CAR-T Therapy Market Size and Growth
5.1. Global CAR-T Therapy Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global CAR-T Therapy Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global CAR-T Therapy Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. CAR-T Therapy Market Segmentation
6.1. Global CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monotherapy
  • Combination Therapy
6.2. Global CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • CD19
  • CD22
  • Other Target Antigens
6.3. Global CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Acute Lymphoblastic Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Other Applications
7. CAR-T Therapy Market Regional and Country Analysis
7.1. Global CAR-T Therapy Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global CAR-T Therapy Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific CAR-T Therapy Market
8.1. Asia-Pacific CAR-T Therapy Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China CAR-T Therapy Market
9.1. China CAR-T Therapy Market Overview
9.2. China CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India CAR-T Therapy Market
10.1. India CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan CAR-T Therapy Market
11.1. Japan CAR-T Therapy Market Overview
11.2. Japan CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia CAR-T Therapy Market
12.1. Australia CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia CAR-T Therapy Market
13.1. Indonesia CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea CAR-T Therapy Market
14.1. South Korea CAR-T Therapy Market Overview
14.2. South Korea CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe CAR-T Therapy Market
15.1. Western Europe CAR-T Therapy Market Overview
15.2. Western Europe CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK CAR-T Therapy Market
16.1. UK CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany CAR-T Therapy Market
17.1. Germany CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France CAR-T Therapy Market
18.1. France CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy CAR-T Therapy Market
19.1. Italy CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain CAR-T Therapy Market
20.1. Spain CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe CAR-T Therapy Market
21.1. Eastern Europe CAR-T Therapy Market Overview
21.2. Eastern Europe CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia CAR-T Therapy Market
22.1. Russia CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America CAR-T Therapy Market
23.1. North America CAR-T Therapy Market Overview
23.2. North America CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA CAR-T Therapy Market
24.1. USA CAR-T Therapy Market Overview
24.2. USA CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada CAR-T Therapy Market
25.1. Canada CAR-T Therapy Market Overview
25.2. Canada CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America CAR-T Therapy Market
26.1. South America CAR-T Therapy Market Overview
26.2. South America CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil CAR-T Therapy Market
27.1. Brazil CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East CAR-T Therapy Market
28.1. Middle East CAR-T Therapy Market Overview
28.2. Middle East CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa CAR-T Therapy Market
29.1. Africa CAR-T Therapy Market Overview
29.2. Africa CAR-T Therapy Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa CAR-T Therapy Market, Segmentation by Target Antigen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa CAR-T Therapy Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. CAR-T Therapy Market Competitive Landscape and Company Profiles
30.1. CAR-T Therapy Market Competitive Landscape
30.2. CAR-T Therapy Market Company Profiles
30.2.1. Gilead Sciences
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Novartis AG
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Biocon
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Gracell Biotechnology Ltd
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Aeon Therapeutics
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. CAR-T Therapy Market Other Major and Innovative Companies
31.1. CARsgen Therapeutics
31.2. Daiichi Sankyo
31.3. Otsuka Pharmaceutical
31.4. Ono Pharmaceutical
31.5. Japan Tissue Engineering
31.6. Nipro Corporation
31.7. Takeda Pharmaceutical Company
31.8. Astellas Pharma
31.9. Innovative Cellular Therapeutics
31.10. Cellular Biomedicine Group
31.11. PersonGen Biomedicine
31.12. Hebei Senlang Biotech
31.13. Adaptimmune(UK)
31.14. Autolus Therapeutics
31.15. BioNTech
32. Global CAR-T Therapy Market Competitive Benchmarking33. Global CAR-T Therapy Market Competitive Dashboard34. Key Mergers and Acquisitions in the CAR-T Therapy Market
35. CAR-T Therapy Market Future Outlook and Potential Analysis
35.1 CAR-T Therapy Market in 2028 - Countries Offering Most New Opportunities
35.2 CAR-T Therapy Market in 2028 - Segments Offering Most New Opportunities
35.3 CAR-T Therapy Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

CAR-T Therapy Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on CAR-T therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for CAR-T therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Type: Monotherapy; Combination Therapy
2) By Target Antigen: CD19; CD22; BCMA; Other Target Antigens
3) By Application: Acute Lymphoblastic Leukemia; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Chronic Lymphocytic Leukemia; Multiple Myeloma; Other Applications

Key Companies Mentioned: Gilead Sciences; Novartis AG; Biocon; Gracell Biotechnology Ltd; Aeon Therapeutics

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Gilead Sciences
  • Novartis AG
  • Biocon
  • Gracell Biotechnology Ltd
  • Aeon Therapeutics
  • CARsgen Therapeutics
  • Daiichi Sankyo
  • Otsuka Pharmaceutical
  • Ono Pharmaceutical
  • Japan Tissue Engineering
  • Nipro Corporation
  • Takeda Pharmaceutical Company
  • Astellas Pharma
  • Innovative Cellular Therapeutics
  • Cellular Biomedicine Group
  • PersonGen Biomedicine
  • Hebei Senlang Biotech
  • Adaptimmune(UK)
  • Autolus Therapeutics
  • BioNTech
  • Cellectis
  • Celyad
  • Crescendo Biologics
  • GammaDelta Therapeutics
  • Immatics
  • Biocad
  • Celgene Corporation
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Amgen
  • AstraZeneca
  • Bayer AG
  • Merck
  • Pfizer
  • Juno Therapeutics
  • Allogene Therapeutics
  • Bluebird Bio Amgen
  • Regen BioPharma
  • OncoSec Medical Incorporated
  • Precision BioSciences
  • Bellicum
  • Sandoz AG
  • GlaxoSmithKline plc
  • Elekta
  • SudairPharma
  • Janssen
  • Aspen
  • Adcock Ingram

Methodology

Loading
LOADING...